Tizanidine-1 (Tizanidine 1)
Tizanidine Tablet
Product Images NDC 82461-721
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 82461-721). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Medcore Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Tizanidine-2 (Tizanidine 2)
Tizanidine-3 (Tizanidine 3)
This text mentions the improvement in Ashworth Score associated with two different doses of tizanidine over time post-dose. The data provided could be part of a study or clinical trial evaluating the effectiveness of tizanidine in reducing muscle spasticity based on the Ashworth Score.*
Tizanidine-4 (Tizanidine 4)
This text indicates the timeline for evaluating the Ashworth Score improvement in a study. The Ashworth Score is often used to assess muscle spasticity in patients. The evaluation is conducted at the end of titration (Study Week 3), at the end of maintenance (Study Week 7), and using the last observation carried forward method for the endpoint.*
2 mg Tablet Bottle Label (Tizanidine 5)
The text provides information about Tizanidine HCI tablets, each containing 2.288 mg of the active ingredient equivalent to 2 mg of tizanidine base. It suggests storing the tablets at 26°C (77°F) with excursions permitted between 15-30°C (59-86°F). The pharmacist information advises dispensing in a tight, light-resistant container, and keeping the medication out of reach of children. The product is distributed by Medcore LLC and the contact information is provided for inquiries. The NDC number, dosage quantity, and expiration date are also listed on the packaging.*
4 mg Tablet Bottle Label (Tizanidine 6)
This text provides details about a tablet containing 4576 mg of tizanidine HCI equivalent to 4 mg of tizanidine base. The dosage information is not specified, so it recommends referring to the package insert. It suggests storing the tablets between 15-30°C (59-86°F). The pharmacist is advised to dispense the medication in a light-resistant container with a child-resistant closure. The product is distributed by Medcore LLC and comes in a package containing 60 tablets. For any inquiries, contact Medcore LLC at the provided address and phone number. The text includes the NDC number, a GTIN, SNO, and expiration date details.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
